Maralixibat

Phase 2

17%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

Oct 2026~

MIRM⭐Phase 3

Maralixibat Phase 3 Results Expected

Maralixibat • Biliary Atresia

Drug Information

Target Indication

Biliary Atresia

Clinical Trial

Last updated: 12/4/2025

Regulatory Approvals

EMAPending

Livmarli

Treatment of progressive familial intrahepatic cholestasis type 2 (PFIC2)

Orphan

Developer

MIRM

Mirum Pharmaceuticals, Inc.

Related Pipeline

CTX

Inborn Errors of Bile Acid Synthesis

Infantile Refsum's Disease

Alagille Syndrome

Primary Biliary Cholangitis